Condition: Generalised Lipodystrophy · Partial Lipodystrophy · Sponsor: Chiesi Farmaceutici S.p.A.
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
This description comes directly from the study's public registry record.
Lori Hartnett · +3905212791 · clinicaltrials_info@chiesi.com
Always discuss trial participation with your own doctor first.
| University Alabama at Birmingham | Birmingham, Alabama, United States | Terminated |
| City of Hope | Duarte, California, United States | Terminated |
| Atlanta Diabetes Associates | Atlanta, Georgia, United States | Completed |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City, Kansas, United States | Recruiting |
| Children's Hospital of New Orleans/LSU Health Sciences Center | New Orleans, Louisiana, United States | Completed |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Withdrawn |
| Nih/Niddk/Deob | Bethesda, Maryland, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Childrens Hospital of Michigan | Detroit, Michigan, United States | Recruiting |
| Richmond University Medical Centre | Staten Island, New York, United States | Completed |
| Endocrinology Research Associates | Columbus, Ohio, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02325674